Objectives: The aim of this study was to determine the influence of sub-Tenon triamcinolone acetonide added to intravitreal bevacizumab on reduction of macular edema. Materials and methods: The study included 21 patients with macular edema (CST > 250 μm) in whom administration of at least 3 intravitreal injections of bevacizumab did not lead to a satisfactory improvement in macular edema. Five patients were diagnosed with senile macular degeneration, three with central retinal vein occlusion, and thirteen with diabetic macular edema. All of them were treated during 2019 at the Department of Ophthalmology, University Hospital of Split. Once edema resistance was established, patients were referred to intravitreal application of bevacizumab together with sub-Tenon injection of triamcinolone. Intraocular pressure screening was performed one day after the procedure and at each subsequent ophthalmic examination, which, in addition to intraocular pressure measurements, included visual acuity, OCT scan of the macula and fundus examination, and were performed 1 and 3 months after injection. Results: Patients received an average of 8.14 injections of intravitreal bevacizumab ± 3.7 prior to the above combination injection. Visual acuity after one month of injection improved in 12 patients (57%) compared to baseline visual acuity, while after 3 months it remained improved in 10 patients (47%). After one month of injection, there was a statistically significant improvement in average visual acuity (+0.05). After three months, the value of average visual acuity did not change significantly from baseline (+0.03). The results showed a statistically significant decrease in CST after one (-154.96 μm) and after 3 months (-106.57 μm) from injection. After one month, the value of CST decreased in 18 patients (85%), and after 3 months the same occurred in 15 patients (71%). The average intraocular pressure value increased by 1 mmHg after 3 months. Conclusions: A statistically significant decrease in macular edema after sub-Tenon injection of triamcinolone acetonide was found in patients who did not respond to repeated monotherapy with intravitreal bevacizumab.